Oncologie

, Volume 15, Issue 2, pp 106–110 | Cite as

Cancers cutanés après transplantation : quoi de neuf ?

Mise au Point / Update

Résumé

Les cancers cutanés sont les cancers les plus fréquents après transplantation d’organe atteignant à long terme 60 à 75 % des patients. Ils comportent en majorité les carcinomes surtout spinocellulaires et basocellulaires, mais aussi le mélanome, la maladie de Kaposi ou d’autres tumeurs plus rares comme le carcinome à cellules de Merkel. La prise en charge de ces tumeurs doit être multidisciplinaire et comprend à la fois des traitements dermatologiques et une révision de l’immunosuppression. La prévention repose sur une protection solaire stricte et un traitement précoce des lésions prémalignes.

Mots clés

Carcinome spinocellulaire Immunosuppression Transplantation d’organe Inhibiteurs de la protéine mTOR Protection solaire 

Skin cancer after transplantation: what’s new?

Abstract

Skin cancers are the commonest cancers after organ transplantation, affecting in the long term 60–75% of the patients. They include mostly carcinomas, especially squamous and basal cell carcinomas, but also melanoma, Kaposi’s sarcoma and other rare skin tumours such as Merkel cell carcinoma. The management of these tumours necessitates a multidisciplinary approach comprising dermatological treatments and revision of immunosuppression. Prevention consists of strict sun protection and early treatment of premalignant lesions.

Keywords

Squamous cell carcinoma Immunosuppression Organ transplantation mTOR inhibitors Sun protection 

Preview

Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.

Références

  1. 1.
    Alberu J, Pascoe MD, Campistol JM, et al. (2011) Lower malignancy rates in renal allograft recipients converted to sirolimus-based, calcineurin inhibitorfree immunotherapy: 24-month results from the CONVERT trial. Transplantation 92: 303–310PubMedCrossRefGoogle Scholar
  2. 2.
    Dantal J, Hourmant M, Cantarovich D, et al. (1998) Effect of long-term immunosuppression in kidney-graft recipients on cancer incidence: randomised comparison of two cyclosporin regimens. Lancet 351: 623–628PubMedCrossRefGoogle Scholar
  3. 3.
    De Gruijl F, Koehl GE, Voskamp P, et al. (2010) Early and late effects of the immunosuppressants rapamycin and mycophenolate mofetil on UV carcinogenesis. Int J Cancer 127: 796–804PubMedGoogle Scholar
  4. 4.
    Duncan FJ, Wulff BC, Tober KL, et al. (2007) Clinically relevant immunosuppressants influence UVB-induced tumor size through effects on inflammation and angiogenesis. Am J Transplant 7: 2693–2703PubMedCrossRefGoogle Scholar
  5. 5.
    Euvrard S, Boissonnat P, Roussoulières A, et al. (2009) Effect of everolimus on skin cancer in calcineurin inhibitor treated heart transplant recipients. Transplant Int 23(8): 855–857CrossRefGoogle Scholar
  6. 6.
    Euvrard S, Claudy A (2009) Posttransplant skin cancer: the influence of organ and pretransplant disease. Cancer Treat Res 146: 65–74PubMedCrossRefGoogle Scholar
  7. 7.
    Euvrard S, Kanitakis J, Claudy A (2003) Skin cancers after organ transplantation. N Engl J Med 348: 1681–1691PubMedCrossRefGoogle Scholar
  8. 8.
    Euvrard S, Kanitakis J, Decullier E, et al. (2006) Subsequent skin cancers in kidney and heart transplant recipients after the first squamous cell carcinoma. Transplantation 81: 1093–1100PubMedCrossRefGoogle Scholar
  9. 9.
    Euvrard S, Morelon E, Rostaing L, et al. (2012) Sirolimus and secondary skincancer prevention in kidney transplantation. N Engl J Med 367: 329–339PubMedCrossRefGoogle Scholar
  10. 10.
    Frances C, Marcelin AG, Legendre C, et al. (2009) The impact of preexisting or acquired Kaposi sarcoma herpesvirus infection in kidney transplant recipients on morbidity and survival. Am J Transplant 9: 2580–2586PubMedCrossRefGoogle Scholar
  11. 11.
    Guba M, Graeb C, Jauch KW, Geissler EK (2004) Pro- and anticancer effects of immunosuppressive agents used in organ transplantation. Transplantation 77: 1777–1782PubMedCrossRefGoogle Scholar
  12. 12.
    Harwood CA, Mesher D, McGregor JM, et al. (2012) A surveillance model for skin cancer in organ transplant recipients: a 22-year prospective study in an ethnically diverse population. Am J Transplant (Epub ahead of print)Google Scholar
  13. 13.
    Hofbauer GF, Attard NR, Harwood CA, et al. (2012) Reversal of UVA skin photosensitivity and DNA damage in kidney transplant recipients by replacing azathioprine. Am J Transplant 12: 218–225PubMedCrossRefGoogle Scholar
  14. 14.
    Jensen AO, Thomsen HF, Engebjerg MC, et al. (2008) Use of photosensitising diuretics and risk of skin cancer: a population-based case-control study. Br J Cancer 99: 1522–1528PubMedCrossRefGoogle Scholar
  15. 15.
    Joly P, Bastuji-Guérin S, Francès C, et al. (2010) Squamous cell carcinomas are associated with verrucokeratotic cutaneous lesions but not with common warts in organ-transplant patients. A casecontrol study. Transplantation 89: 1224–1230CrossRefGoogle Scholar
  16. 16.
    Kassem A, Technau K, Kurz AK, et al. (2009) Merkel cell polyomavirus sequences are frequently detected in nonmelanoma skin cancer of immunosuppressed patients. Int J Cancer 125: 356–361PubMedCrossRefGoogle Scholar
  17. 17.
    Koehl GE, Andrassy J, Guba M, et al. (2004) Rapamycin protects allografts from rejection while simultaneously attacking tumors in immunosuppressed mice. Transplantation 77: 1319–1326PubMedCrossRefGoogle Scholar
  18. 18.
    Nichols LA, Adang LA, Kedes DH (2011) Rapamycin blocks production of KSHV/ HHV8: insights into the anti-tumor activity of an immunosuppressant drug. PLoS One 6: e14535PubMedCrossRefGoogle Scholar
  19. 19.
    Proby CM, Harwood CA, Neale RE, et al. (2011) A case-control study of betapapillomavirus infection and cutaneous squamous cell carcinoma in organ transplant recipients. Am J Transplant 11: 1498–1508PubMedCrossRefGoogle Scholar
  20. 20.
    Rival-Tringali AL, Euvrard S, Decullier E, et al. (2009) Conversion from calcineurin inhibitors to sirolimus reduces vascularization and thickness of post-transplant cutaneous squamous cell carcinomas. Anticancer Res 29: 1927–1932PubMedGoogle Scholar
  21. 21.
    Spangle JM, Munger K (2010) The human papillomavirus type 16 E6 oncoprotein activates mTORC1 signaling and increases protein synthesis. J Virol 84: 9398–9407PubMedCrossRefGoogle Scholar
  22. 22.
    Stallone G, Schena A, Infante B, et al. (2005) Sirolimus for Kaposi’s sarcoma in renal-transplant recipients. N Engl J Med 352: 1317–1323PubMedCrossRefGoogle Scholar
  23. 23.
    Ulrich C, Kanitakis J, Stockfleth E, Euvrard S (2008) Skin cancer in organ transplant recipients: where do we stand today? Am J Transplant 8: 2192–2198PubMedCrossRefGoogle Scholar
  24. 24.
    Vajdic CM, Van Leeuwen MT, Webster AC, et al. (2009) Cutaneous melanoma is related to immune suppression in kidney transplant recipients. Cancer Epidemiol Biomarkers Prev 18: 2297–2303PubMedCrossRefGoogle Scholar
  25. 25.
    Wisgerhof HC, Edelbroek JR, de Fijter JW, et al. (2010) Subsequent squamousand basal-cell carcinomas in kidney-transplant recipients after the first skin cancer: cumulative incidence and risk factors. Transplantation 89: 1231–1238PubMedCrossRefGoogle Scholar
  26. 26.
    Wisgerhof HC, Van der Boog PJ, de Fijter JW, et al. (2009) Increased risk of squamous cell carcinoma in simultaneous pancreas kidney transplant recipients compared with kidney transplant recipients. J Invest Dermatol 129: 2886–2894PubMedCrossRefGoogle Scholar
  27. 27.
    Wisgerhof HC, Wolterberk R, de Fijter JW, et al. (2012) Kidney transplant recipients with cutaneous squamous cell carcinoma have an increased risk of internal malignancy. J Invest Dermatol 132: 2176–2183PubMedCrossRefGoogle Scholar
  28. 28.
    Zwald FO, Brown M (2011) Skin cancer in solid organ transplant recipients: advances in therapy and management. Part II: management of skin cancer in solid organ transplant recipients. J Am Acad Dermatol 65: 253–261PubMedCrossRefGoogle Scholar
  29. 29.
    Zwald FO, Christenson LJ, Billingsley EM, et al. (2012) Melanoma in solid organ transplant recipients. Am J Transplant 10: 1–8Google Scholar
  30. 30.
    Zwald FO, Spratt M, Lemos BD, et al. (2012) Duration of voriconazole exposure: an independent risk factor for skin cancer after lung transplantation. Dermatol Surg 38: 1369–1374PubMedCrossRefGoogle Scholar

Copyright information

© Springer-Verlag France 2013

Authors and Affiliations

  1. 1.Service de dermatologie, unité spécialisée dans le suivi des greffés d’organehôpital Édouard-HerriotLyon cedex 03France

Personalised recommendations